Shots:
- The P- III trial involves assessing of Keytruda in combination with ipilimumab vs Keytruda monothx in 568 patients in a ratio (1:1) as 1L treatment for metastatic NSCLC patients without EGFR or ALK genomic tumor aberrations and whose tumors express PD-L1
- Results: @ median follow-up (20.6 mos.); mOS (21.4 vs 21.9 mos.); mPFS (8.2 vs 8.4 mos.); ORR (45.4%); mDOR (16.1 mos.); RMST ( -0.56 and -0.52) @24 mos.
- The results were presented in the Presidential Symposium at the World Conference on Lung Cancer 2020 Presidential Symposium and published in the Journal of Clinical Oncology
Click here to read full press release/ article | Ref: Businesswire | Image: AP News
The post Merck’s Report Results of Keytruda (pembrolizumab) in Combination With Ipilimumab vs Keytruda Monotherapy in P-III KEYNOTE-598 for Metastatic Non-Small Cell Lung Cancer Patients first appeared on PharmaShots.